(Q38533544)

3 September 2017

1 reference

title

MELAS syndrome: Clinical manifestations, pathogenesis, and treatment options (English)

1 reference

3 September 2017

1 reference

1

Ayman W El-Hattab

1 reference

3 September 2017

4

Fernando Scaglia

1 reference

3 September 2017

Adekunle M Adesina

2

1 reference

3 September 2017

Jeremy Jones

series ordinal

3

1 reference

3 September 2017

publication date

15 June 2015

1 reference

Molecular Genetics and Metabolism

3 September 2017

published in

1 reference

3 September 2017

volume

116

1 reference

3 September 2017

issue

1-2

1 reference

3 September 2017

page(s)

4-12

1 reference

Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: A distinctive clinical syndrome

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

A point mutation in the mitochondrial tRNA(Leu)(UUR) gene in MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Melas: an original case and clinical criteria for diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

MELAS: a nationwide prospective cohort study of 96 patients in Japan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes: prevalence of the mutation in an adult population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Prevalence, segregation, and phenotype of the mitochondrial DNA 3243A>G mutation in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current concepts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Mitochondrial encephalopathy, lactic acidosis, and strokelike episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Cerebral lactic acidosis correlates with neurological impairment in MELAS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Focal and Generalized Seizures May Occur in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Strokelike Episodes (MELAS) Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

MELAS presenting as migraine complicated by stroke: case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Peripheral neuropathy in patients with the 3243A>G mutation in mitochondrial DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Nerve conduction abnormalities in patients with MELAS and the A3243G mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

The psychiatric manifestations of mitochondrial disorders: a case and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Wolff-Parkinson-White syndrome in Patients With MELAS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

A follow up study of myocardial involvement in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Gastric dysmotility associated with accumulation of mitochondrial A3243G mutation in the stomach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Mitochondrial diabetes: molecular mechanisms and clinical presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Nephropathy and growth hormone deficiency in a patient with mitochondrial tRNA(Leu(UUR)) mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Endocrine disorders in two sisters affected by MELAS syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

mtDNA nt3243 mutation, external ophthalmoplegia, and hypogonadism in an adolescent girl

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Clinical and pathologic features of focal segmental glomerulosclerosis with mitochondrial tRNALeu(UUR) gene mutation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Increased prevalence of vitiligo, but no evidence of premature ageing, in the skin of patients with bp 3243 mutation in mitochondrial DNA in the mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome (MELAS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Skin manifestations of a patient with mitochondrial encephalomyopathy with lactic acidosis and strokelike episodes (MELAS syndrome).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Pathogenic mitochondrial DNA mutations in protein-coding genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

POLG1 mutations and stroke like episodes: a distinct clinical entity rather than an atypical MELAS syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Defects in mitochondrial protein synthesis and respiratory chain activity segregate with the tRNA(Leu(UUR)) mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

The mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episode syndrome-associated human mitochondrial tRNALeu(UUR) mutation causes aminoacylation deficiency and concomitant reduced association of mRNA with ribosomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Strongly succinate dehydrogenase-reactive blood vessels in muscles from patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): a correlative study of the clinical features and mitochondrial DNA mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Restoration of impaired nitric oxide production in MELAS syndrome with citrulline and arginine supplementation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Citrulline and arginine utility in treating nitric oxide deficiency in mitochondrial disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Mitochondria: role of citrulline and arginine supplementation in MELAS syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Arginine metabolism: nitric oxide and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Effect of exercise training on endothelium-derived nitric oxide function in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

The pharmacology of nitric oxide in the peripheral nervous system of blood vessels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Hypocitrullinemia in patients with MELAS: an insight into the "MELAS paradox".

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

The role of nitric oxide in muscle fibers with oxidative phosphorylation defects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Metabolically induced heteroplasmy shifting and l-arginine treatment reduce the energetic defect in a neuronal-like model of MELAS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Cellular ADMA: regulation and action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Increased protein nitration in mitochondrial diseases: evidence for vessel wall involvement.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

L-arginine improves the symptoms of strokelike episodes in MELAS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Glucose metabolism derangements in adults with the MELAS m.3243A>G mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Microvascular dysfunction in obesity: a potential mechanism in the pathogenesis of obesity-associated insulin resistance and hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

The role of mitochondria in insulin resistance and type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

The UK MRC Mitochondrial Disease Patient Cohort Study: clinical phenotypes associated with the m.3243A>G mutation--implications for diagnosis and management.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Heterogeneous presentation in A3243G mutation in the mitochondrial tRNA(Leu(UUR)) gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

The A to G transition at nt 3243 of the mitochondrial tRNALeu(UUR) may cause an MERRF syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Muscle phenotype and mutation load in 51 persons with the 3243A>G mitochondrial DNA mutation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Implications of exercise training in mtDNA defects--use it or lose it?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

The mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

MELAS and L-arginine therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Endothelial dysfunction in MELAS improved by l-arginine supplementation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

The effect of citrulline and arginine supplementation on lactic acidemia in MELAS syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

A randomized trial of coenzyme Q10 in mitochondrial disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Long-term treatment with idebenone and riboflavin in a patient with MELAS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Effect of long-term oral treatment with L-arginine and idebenone on the prevention of stroke-like episodes in an adult MELAS patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

CPEO and carnitine deficiency overlapping in MELAS syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243G mutation of mitochondrial DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Cigarette smoke-induced blockade of the mitochondrial respiratory chain switches lung epithelial cell apoptosis into necrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

Diabetes mellitus, deafness, muscle weakness and hypocalcemia in a patient with an A3243G mutation of the mitochondrial DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2015.06.004

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YMGME.2015.06.004

1 reference

3 September 2017

1 reference